RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .
The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia
Objective : Mixed dyslipidemia , oxidative stress and inflammation are related to a high risk for cardiovascular events . The aim of this open-label r and omized study was to compare the effects of high-dose rosuvastatin , low-dose rosuvastatin plus fenofibrate and low-dose rosuvastatin plus omega 3 fatty acids on inflammation and oxidative stress indices in patients with mixed dyslipidemia . Methods : Ninety patients with mixed dyslipidemia participated in the study . Patients were r and omly allocated to receive rosuvastatin 40 mg ( n = 30 , group R ) , rosuvastatin 10 mg plus fenofibrate 200 mg ( n = 30 , group RF ) or rosuvastatin 10 mg plus omega 3 fatty acids 2 g daily ( n = 30 , group RΩ ) . Plasma and high-density lipoprotein (HDL)-associated lipoprotein-associated phospholipase A2 ( LpPLA2 ) activities , high-sensitivity C reactive protein ( hsCRP ) , plasma isoprostane and paraoxonase ( PON1 ) activities were measured at baseline and after 3 months of treatment . Results : Serum concentrations of non-HDL cholesterol and low-density lipoprotein cholesterol ( LDL-C ) were significantly reduced in all study groups . However , these changes were more pronounced in the rosuvastatin monotherapy group . In all treatment groups a significant reduction in total plasma LpPLA2 activity was observed ( by 41 , 38 and 30 % for groups R , RF and RΩ , respectively ) . This decrease was greater in the R and RF groups compared with the RΩ combination ( p < 0.05 ) . HDL-LpPLA2 activity was increased more in the RF group ( + 43 % ) compared with the R and RΩ groups ( + 18 % and + 35 % , respectively ; p < 0.05 for both comparisons ) . In all treatment groups there was a nonsignificant reduction in plasma 8-iso-PGF2α levels . A 53 % reduction of hsCRP levels was observed in the R group , while in the RF and RΩ groups the reduction was 28 and 23 % , respectively ( p < 0.05 and p < 0.01 for the comparisons of group R with groups RF and RΩ , respectively ) . No significant changes were observed in PON activities in all treatment groups . Conclusion : The greater non-HDL-C- and LDL-C-lowering  efficiency of rosuvastatin monotherapy along with its more potent effect on LpPLA2 activity and hsCRP levels indicate that this regimen is a better treatment option for patients with mixed dyslipidemia
RESULTS Meta- analysis suggested that statin therapy is associated with a significant elevation of PON1 paraoxonase and arylesterase activities , but not PON1 protein concentration .
The PON1-enhancing effects of statins were robust in the sensitivity analyses and were independent of statin dose , treatment duration and changes in plasma low-density lipoprotein cholesterol concentration .
CONCLUSION The increase of paraoxonase and arylesterase activities with statins is a pleiotropic lipid-independent clinical benefit that may partly explain the putative effects of statins in preventing cardiovascular outcomes
BACKGROUND Decreased activity of the enzyme paraoxonase-1 ( PON1 ) has been demonstrated in cardiovascular diseases .
Statins , the forefront of pharmacotherapy for dyslipidemia , have been shown to enhance PON1 activity but clinical findings have not been conclusive .
OBJECTIVE To systematic ally review the clinical findings on the impact of statin therapy on PON1 status ( protein concentrations and activities of paraoxonase and arylesterase ) and calculate an effect size for the mentioned effects through meta- analysis of available data .